Clarity Pharmaceuticals Ltd (CLRPF PINK) stock market data APIs
$2.2106
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
Clarity Pharmaceuticals Ltd Financial Data Overview
Price chart is built with
Anychart
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Prev. Close
2.2106
Open
2.2106
High
2.2106
Low
2.2106
52 wk Range
0.842-6.398
Market Cap
828 M
Shares Outstanding
372 M
Revenue
9 463 K
Beta
1.33
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Clarity Pharmaceuticals Ltd data using free add-ons & libraries
Get Clarity Pharmaceuticals Ltd Fundamental Data
Clarity Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue: 9 463 K
- EBITDA: -68 908 944
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-18
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Clarity Pharmaceuticals Ltd News
New
Top ASX Growth Stocks With High Insider Ownership In July 2025
As the Australian market navigates a landscape marked by an unexpected unemployment rate of 4.3% and potential interest rate cuts, investor sentiment is cautiously optimistic amid ongoing global trade...
ASX Penny Stocks Spotlight: Clarity Pharmaceuticals And 2 More Standouts
The Australian market is poised for a rebound, with shares expected to rise following Wall Street's positive momentum, largely driven by Nvidia's remarkable performance. In the context of this optimis...
ASX Penny Stocks: 3 Picks With Market Caps Under A$700M
The Australian stock market is experiencing a significant upswing, with the ASX 200 reaching new heights amid optimism from positive U.S.-China trade discussions. In this context, penny stocks—often...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
